To summarize the mechanistic rationale, clinical evidence, translational barriers, and future prospects of antibody-based therapies for diabetic kidney disease (DKD).
Approach:
Literature Review: Conducted a narrative literature review using PubMed, Cochrane Library, and ClinicalTrials.gov from inception to March 31, 2026, focusing on peer-reviewed studies and clinical trials related to mAb strategies targeting DKD.
Key Findings:
Phase II studies of anti-TGF-β1 and anti-VEGF-B antibodies failed to show meaningful renal benefit.
Anti-CTGF therapy showed an early signal of albuminuria reduction.
Anti-suPAR remains under clinical evaluation.
Emerging preclinical targets, including integrin αvβ8 and signal regulatory protein α, may provide more kidney-focused modulation of fibrotic and inflammatory pathways.
PCSK9 monoclonal antibodies, particularly evolocumab and alirocumab, may confer renal benefit through lipid lowering and kidney-intrinsic effects on lipotoxicity, oxidative stress, AMPK signaling, and profibrotic pathways.
Interpretation:
Monoclonal antibodies present a biologically compelling but clinically underdeveloped strategy for DKD treatment.
Limitations:
Challenges include pathway redundancy, delayed intervention, insufficient intrarenal target engagement, and off-kidney toxicity.
Conclusion:
Future progress in monoclonal antibody therapies for diabetic kidney disease will require earlier biomarker-informed patient selection, confirmation of intrarenal target engagement, appropriate renal endpoints, and rational combination with established therapies.
